scholarly journals Immunotherapy of Prostate Cancer Patients could Overexpress The Virulence Factor Genes of E.faecalis

2017 ◽  
pp. 15-18
Author(s):  
Tayebe Talebzade ◽  
Fahimeh Baghbani-arani ◽  
Soha Sadeghi ◽  
Arvin Haghighatfard ◽  
Niloofar Ahmadi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Side Effects ◽  
Cancer Patients ◽  
Enterococcus Faecalis ◽  
Mrna Level ◽  
Surface Protein ◽  
Normal Subjects ◽  
Intestinal Infections ◽  
Immunotherapy Of Cancer ◽  
Group B

Prostate cancer is the most prevalent and second cause of death from cancer in men worldwide. Immunotherapy is a new method for the treatment of several cancers that fights cancer cells by strengthening the immune system through some medications. While immunotherapy is a useful method for cancer treatment; its side effects still are not totally clarified. Numbers of prostate cancer patients which take immunotherapy are experiencing prostate inflammation and prostatitis after treatment period. Enterococcus faecalis is Gram-positive and catalase-negative cocci that are common in the intestines of humans and other animals and cause most enterococcal infections such as intestinal infections, prostatitis, gastroenteritis and endocarditic. Present study aimed to evaluate the mRNA level of virulence genes which are involved in Enterococcus faecalis pathogenesis in prostate cancer patients that treated by immunotherapy. Expression level of gelatinase E (gelE) and Enterococcal surface protein (esp) genes were examined by Real time PCR in three groups of 68 male subjects. Group A normal subjects, group B prostate cancer patients before start treatment and group C prostate cancer patients after six months immunotherapy period. Results were showed significant (P<0.05) over expression of both genes (gelE and esp ) in group C against the group B. According to the results, it is reasonable that immunotherapy may have side effects such as increasing the pathogenicity risk of microflora in patients. Maybe these side effects could cause further infections after ending the immunotherapy of cancer. Antibiotic usage after or at the same time of immunotherapy period could prevent possible infections of microflora including E. faecalis.

1126 Role of Polymorphisms in the ERCC2 Gene in the Development of Severe Side Effects After Radiotherapy of Prostate Cancer Patients

2012 ◽  
Vol 48 ◽  
pp. S271
Author(s):  
E.M. Thurner ◽  
S. Krenn-Pilko ◽  
W. Renner ◽  
J. Szkandera ◽  
A. Gerger ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Side Effects ◽  
Cancer Patients

In vivo versus in vitro individual radiosensitivity analysed in healthy donors and in prostate cancer patients with and without severe side effects after radiotherapy

2012 ◽  
Vol 88 (5) ◽  
pp. 405-413 ◽  
Author(s):  
Kinga Brzozowska ◽  
Michael Pinkawa ◽  
Michael J. Eble ◽  
Wolfgang-Ullrich Müller ◽  
Andrzej Wojcik ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Side Effects ◽  
Cancer Patients ◽  
Individual Radiosensitivity ◽  
Healthy Donors

scholarly journals Drug Intensification in Future Postoperative Radiotherapy Practice in Biochemically-Relapsing Prostate Cancer Patients

2021 ◽  
Vol 11 ◽  
Author(s):  
Axel Cailleteau ◽  
Paul Sargos ◽  
Fred Saad ◽  
Igor Latorzeff ◽  
Stéphane Supiot
Keyword(s):  
Prostate Cancer ◽  
Dna Repair ◽  
Androgen Receptor ◽  
Side Effects ◽  
Cancer Patients ◽  
Postoperative Radiotherapy ◽  
Novel Agents ◽  
Preclinical Studies ◽  
Phase 3 ◽  
Prostate Bed

Although salvage prostate bed radiotherapy is highly effective in biochemically-relapsing prostate cancer patients following prostatectomy, relapses remain frequent and improvements are needed. Randomized phase 3 trials have shown the benefit of adding androgen-depriving therapy to irradiation, but not all patients benefit from this combination. Preclinical studies have shown that novel agents targeting the androgen receptor, DNA repair, PI3K/AKT/mTOR pathways, or the hypoxic microenvironment may help increase the response to prostate bed irradiation while minimizing potential side effects. This perspective review focuses on the most relevant molecules that may have an impact when combined with salvage radiotherapy, and underlines the strategies that need to be developed to increase the efficacy of salvage post-prostatectomy radiotherapy in prostate cancer patients.

scholarly journals Comparison of EBRT and I-125 seed brachytherapy concerning outcome in intermediate-risk prostate cancer

2021 ◽  
Author(s):  
Matthias Moll ◽  
Andreas Renner ◽  
Christian Kirisits ◽  
Christopher Paschen ◽  
Alexandru Zaharie ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Side Effects ◽  
Cancer Patients ◽  
External Beam Radiotherapy ◽  
External Beam ◽  
Intermediate Risk ◽  
Risk Prostate Cancer ◽  
Gastrointestinal Side Effects ◽  
Over Time

Abstract Purpose This study’s objective was the comparison of external beam radiotherapy (EBRT) and I‑125 seed brachytherapy regarding clinical outcome and development of side effects. Patients and methods In all, 462 localized intermediate-risk prostate cancer patients treated between 2000 and 2019 at our department using either I‑125 seed brachytherapy or EBRT with a dose of 74 or 78 Gy were included: 297 patients were treated with EBRT and 165 with seeds. Biochemical no evidence of disease (bNED) rates according to Phoenix definition as well as late gastrointestinal and urogenital side effects (EORTC/RTOG) were assessed. Results Patients were followed up yearly with a median follow-up of 54 (3–192) months. Observed bNED rates for 74 Gy, 78 Gy and seeds were 87, 92, and 88% after 5 years and 71, 85, and 76% after 9 years, respectively. No significant differences were found comparing seeds with 74 Gy (p = 0.81) and 78 Gy (p = 0.19), as well as between 74 and 78 Gy (p = 0.32). Concerning gastrointestinal side effects, EBRT showed significantly higher rates of RTOG grade ≥ 2 toxicity compared to seeds, but at no point of the follow-up more than 10% of all patients. However, genitourinary side effects were significantly more prevalent in patients treated with seeds, with 33% RTOG grade ≥ 2 toxicity 12 months after treatment. Nevertheless, both types of side effects decreased over time. Conclusion Favorable intermediate-risk prostate cancer patients can be treated either by external beam radiotherapy (74/78 Gy) or permanent interstitial seed brachytherapy.

Sign in / Sign up

Export Citation Format

Share Document